C eliac disease (CD) has a diversity of presentations that include typical symptoms such as diarrhea and weight loss and atypical symptoms such as elevated liver function tests and fatigue. Current guidelines recommend case finding for diagnosis of CD, a technique in which physicians test individuals thought to be at risk for the disease due to the presence of conditions or symptoms associated with CD.
C eliac disease (CD) has a diversity of presentations that include typical symptoms such as diarrhea and weight loss and atypical symptoms such as elevated liver function tests and fatigue. Current guidelines recommend case finding for diagnosis of CD, a technique in which physicians test individuals thought to be at risk for the disease due to the presence of conditions or symptoms associated with CD. 1 However, CD, particularly cases with atypical symptoms, remains largely undiagnosed. 2, 3 Increasing evidence suggests that case finding may not be effective. 4, 5 Given the morbidity of undiagnosed symptomatic CD, a new method of detection needs to be developed. 6 We therefore sought to build a machine learning model for identifying undiagnosed CD based on permutations of currently accepted indications to test for CD.
Methods
Serum samples were collected from 47,557 individuals without prior CD diagnosis, receiving care at Mayo Clinic (Rochester, Minnesota) between 1995 and 2009. A total of 408 undiagnosed cases were identified through sequential serology: a positive or indeterminate immunoglobulin A tissue transglutaminase antibody followed by a positive endomysial antibody. 408 gender-, age-, and year of serum collection-matched controls were selected from individuals with negative composite serology. Medical records were reviewed by a physician blinded to serologic status. Using a standardized collection sheet, they collected data on frequency of indications to test for CD drawn from current guidelines (Supplementary Table 1 ). 1 To identify undiagnosed cases we built a series of predictive models utilizing a variety of statistical approaches: logistic regression, elastic net, tree-based models with and without boosting or bagging, support vector machine with radial basis functions, a neural network (single layer perceptron), random forest, and linear discriminant analysis. All models were built using a grid search over plausible hyperparameters, with performance assessed via area under the receiver-operating characteristic curve on out-of-sample observations during 10-fold cross-validation. Preprocessing consisted of the centering and scaling of all continuous variables, the removal of all zero-variance predictors, and the omission of any records with missing variables (20 observations, 2.5% of our cohort).
Experiments were conducted both including and excluding variables with low variance. This meaningfully affected the performance of only the elastic net, which is unsurprising given its regularization. Due to this minor effect, low-and zero-variance variables were removed, and all results considered here are for the predictor set: sex, age, number of symptoms, history of any autoimmune condition, thyroid disorder, anemia, hypothyroidism, previous indication to test for CD, dyspepsia, and recurring abdominal pain.
Results
Of the 10 models trained, all yielded poor discriminatory performance, with an area under the receiveroperating characteristic curve ranging from 0.49 to 0.53 (Figure 1 ). Only two, the random forest and bagged classification trees, outperformed random chance with a likelihood >95%, and these were not significantly different from the other models.
Discussion
Only 2 models outperformed random chance in identifying undiagnosed CD, and these models had very low predictive power. The inability to develop a successful model suggests that currently used indications to test do not characterize undiagnosed CD. This has significant clinical implications for how providers should screen for CD, which remains largely undetected.
Atypical and asymptomatic cases make up the majority of the estimated 80% of undiagnosed CD. 2 While evidence suggests that atypical cases benefit from diagnosis, the U.S. Preventive Services Task Force recently determined there was insufficient evidence to support screening asymptomatic individuals. 7 Case finding has therefore been proposed to increase detection of atypical cases. However, our findings, along with several recent studies, suggest that case finding is not as effective, and that continued use may not detect most cases with CD. 1, 4, 5 Our failure to develop an effective model may be due to the subtle symptoms in atypical cases and suggests that case finding based on symptoms may be ineffective. Prior studies found that people detected through screening had mild symptoms that went unrecognized until they improved with treatment. 8 If the nature of undiagnosed cases is that symptoms do not come to clinical attention, then case-finding strategies looking for symptoms will not be effective. Conversely, strategies potentially looking at conditions associated with CD or physical exam findings may be more effective. Our study was limited in that it could not accurately evaluate family history, which has previously been associated with a high risk of CD.
In conclusion, we were unable to develop an effective model based on currently used indications to test to identify undiagnosed CD cases. This suggests providers cannot rely on currently accepted symptomatology to determine whom to screen. Case finding based on these symptoms is unlikely to be effective in increasing diagnosis, and new methods need to be explored.
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Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at https://doi.org/10.1016/j.cgh.2017.12.022. Figure 1 . Area under the receiver-operating characteristic curve (AUC) from out-of-sample cross-validation. Only the bagged tree (treebag) and random forest (rf) models outperform random chance. 
